Answers are grounded in this paper and cite their sources.
Tuberculosis (TB) remains a major global health challenge, complicated by prolonged multidrug therapy, treatment-associated toxicity, poor adherence, granuloma-associated drug penetration barriers, and the growing burden of multidrug-resistant and extensively drug-resistant TB. Lipid-based nanomedicine has emerged as a promising strategy to improve anti-tubercular drug delivery by enhancing pulmonary deposition, macrophage-associated uptake, sustained intracellular drug release, and local drug exposure. However, the current evidence base remains largely preclinical, heterogeneous, and insufficiently translated into clinical practice. This narrative review summarizes selected experimental and preclinical reports and relevant reviews on lipid and lipid-associated TB formulations. A focused search of PubMed, Scopus, Web of Science, and Google Scholar covered publications through January 2025, using documented TB, lipid-carrier, pulmonary-delivery, and anti-tubercular drug-delivery terms. Because complete query logs and study-level screening records were unavailable, no formal screening counts or total included-study count are reported. Findings were synthesized narratively. Selected studies report formulation-specific changes in entrapment, macrophage uptake, oral drug exposure, or pulmonary drug exposure. Antibacterial outcomes, resistant-strain experiments, and clinical evidence are much more limited. For MDR-TB and XDR-TB, a carrier might increase exposure to an agent that remains active against the infecting strain, but it cannot alter the bacterial mutations responsible for genetic resistance or replace a susceptibility-guided multidrug regimen. The studies vary by payload, route, comparator, and model, so their endpoints cannot be pooled into a carrier-wide therapeutic effect. Lipid-based nanomedicine offers a promising but still translationally immature approach to optimizing TB drug delivery. Its main potential lies in improving pulmonary targeting, macrophage delivery, sustained drug release, granuloma-associated drug exposure, and second-line drug delivery for resistant TB. However, major barriers remain, including formulation stability, scalable manufacturing, inhalation-device compatibility, long-term pulmonary safety, regulatory complexity, cost constraints, and the lack of clinical trial evidence in TB. Future research should prioritize standardized preclinical models, lesion-relevant pharmacokinetic and pharmacodynamic studies, repeated-dose safety assessment, scalable manufacturing strategies, and early-phase clinical trials to determine whether lipid-based nanocarriers can achieve meaningful therapeutic benefit in TB management.
No takes yet. Share an insight, caveat, or question.
Tariq et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: